Table 2. Main Baseline characteristics of patients with 2-years follow-up according to dialysis modality.
| PDa patients | HDb patients | p | |
|---|---|---|---|
| (n = 82) | (n = 85) | ||
| Males (%) | 47 (57.3) | 48 (52.2) | 0.6 |
| Age (years) | 53 [42.5;63] | 55 [44.8;64] | 0.39 |
| Smoker (former/current) (%) | 49 (59.8) | 48 (52.2) | 0.9 |
| Diabetes (%) | 14 (17.1) | 14 (15.2) | 0.9 |
| Hypertension (%) | 75 (91.5) | 79 (86) | 0.359 |
| Dyslipidemia (%) | 58 (70.7) | 55 (59.8) | 0.176 |
| Etiology of renal disease (%): | 0.670 | ||
| Diabetic nephropathy | 7 (8.54) | 8 (8.7) | |
| Vascular disease | 8 (9.76) | 13 (14.1) | |
| Others | 67 (81.7) | 71 (77.2) | |
| Dialysis time (months) | 10.5 [4.46;19.2] | 11.5 [5.82;25.8] | 0.131 |
| Body mass index (kg/m2) | 26.4 [23.3;28.4] | 26.1 [23;4.32.2] | 0.446 |
| Systolic Blood Pressure (mmHg) | 145 (24.4) | 138 (21.8) | 0.03 |
| Diastolic Blood Pressure (mm Hg) | 87.5 (12.2) | 78.8 (13.3) | <0.001 |
| Pulse Pressure (mmHg) | 56 [44;69] | 56.5 [47;70.2] | 0.579 |
| Serum glucose (mmol/L) | 5.16 [4.72;5.61] | 5.23 [4.55;6.05] | 0.931 |
| Urea (mmol/L) | 22.11 (6.76) | 20.31 (6.13) | 0.053 |
| Creatinine (μmol/L) | 596.7 [468.5;792.1] | 676.3 [583.4;837.2] | 0.815 |
| Total colesterol (mmol/L) | 4.75 [4.2;5.43] | 3.9 [3.2;4.45] | 0.258 |
| HDL-cholesterol (mmol/L) | 1.21 [1;1.52] | 1.1 [0.88;1.21] | 0.005 |
| LDL-cholesterol (mmol/L) | 3.46 [2.28;3.05] | 3.36 [2.56;4.4] | <0.001 |
| Triglycerides (mmol/L) | 1.53 [1.09;2.02] | 1.48 [1.13;1.94] | 0.940 |
| Serum uric acid (μmol/L) | 350.4 (72.6) | 369.4 (70.78) | 0.093 |
| hs C-Reactive Protein (nmol/L) | 26.28 [10;61.24] | 24 [10.47;62.48] | 0.815 |
| Albumin (mol/L) | 0.59 [0.53;0.62] | 0.59 [0.54;0.64] | 0.471 |
| Hemoglobin (mmol/L) | 7.24 (0.80) | 6.82 (0.84) | 0.002 |
| Corrected calcium (mmol/L) | 2.32 [2.22;2.4] | 2.25 [2.16;2.32] | 0.031 |
| Phosphate (mmol/L) | 1.52[1.32;1.81] | 1.55 [1.29;1.81] | 0.965 |
| iPTH (pmolL) | 21.1 [15.48;34.25] | 26.51 [16.2;41] | 0.182 |
| 25-hydroxy-vitamin D (nmol/L) | 30.5 [21.75;43.75] | 35.5 [27;48] | 0.014 |
| 1-25-hydroxy-vitamin D (pmol/L) | 15.45 [10.3;22.7] | 14.4 [10.15;25.75] | 0.862 |
| Treatments | |||
| Antihypertensive (%): | 72 (87.8) | 60 (65.2) | 0.001 |
| ACEIc (%) | 20 (24.4) | 15 (16.3) | 0.255 |
| ARBsd (%) | 37 (45.1) | 25 (27.2) | 0.021 |
| Diuretics (%) | 27 (32.6) | 28 (32.9) | 0.837 |
| Statins (%) | 48 (58.3) | 50 (54.3) | 0.687 |
| Phosphate binders (%): | 66 (80.5) | 68 (73.9) | 0.396 |
| Binders without Cae (%) | 38 (46.3) | 48(52.2) | 0.538 |
| Binders with Cae (%) | 42 (47.2) | 40 (47.1) | 1 |
| Cae intake (binders) (gr/day) | 1 [1;1.5] | 1.5 [1;2.5] | 0.03 |
| Calcitriol/Paricalcitol (%) | 34 (41.5) | 44 (47.8) | 0.490 |
| Calcifedol /%) | 8 (9.76) | 5 (5.43) | 0.428 |
| Cholecalciferol (%) | 2 (2.44) | 4 (4.35) | 0.685 |
| Cinacalcet (%) | 18 (22) | 24 (26.1) | 0.646 |
| Antiplatelet drugs (%): | 22 (26.8) | 27 (29.3) | 0.842 |
| ESAf (%) | 62 (75.6) | 77 (83.7) | 0.255 |
| Renal transplantation centre (%) | 27 (32.9) | 20 (21.7) | 0.137 |
| Plaque presence (%) | 44 (53.7) | 53 (57.6) | 0.711 |
| Number of territories with plaque | 2 [1.0;2.0] | 2 [1.0;3.0] | 0.149 |
| cIMTg (mm) | 0.65 [0.57;0.75] | 0.72 [0.62;0.86] | 0.005 |
| Ankle-Brachial index (%) | <0.001 | ||
| ABI <0.9 | 10 (12.2) | 7 (7.78) | |
| ABI >0.9-<1.4 | 66 (80.5) | 55 (61.1) | |
| ABI > 1.4 | 6 (7.32) | 21 (31.1) |
Data are presented as median [interquartile range], mean (standard deviation) or n (%).
a Peritoneal dialysis
b Hemodialysis
c Angiotensin converting enzyme inhibitors
d Angiotensin II receptor blockers
e Calcium
f Erythropoiesis stimulating agents
g Common carotid artery intima media thickness